News

Potent human broadly SARS-CoV-2–neutralizing IgA and IgG antibodies effective against Omicron BA.1 and BA.2

SPIKIMM receives 15 Million Euros in non-dilutive funding awarded by France 2030 to accelerate the clinical and industrial development of its monoclonal antibodies against SARS-COV-2

SPIKIMM, a biotech company founded by Truffle Capital and Institut Pasteur, announce that SPK001, its monoclonal antibody has demonstrated a potent and broad neutralization activity across all SARS-COV-2 variants of concern, including Omicron (BA.1 AND BA.2)

Coronavirus variants are dodging antibody treatments. New lab-made options may help

Long-term benefits of clean energy sources

SpikImm announces the signature of an exclusive license option and
collaboration agreement with SATT Conectus

France 2030 : la recherche et l’innovation au cœur des enjeux pour prévenir et lutter contre les maladies infectieuses émergentes et les menaces nucléaire, radiologique, biologique et chimique

SPIKIMM, a biotechnology company founded by Truffle Capital under license from the Institut Pasteur, announces that the clinical trials for SPK001, its monoclonal antibody against SARS-COV-2, have begun

‘Super-antibodies’ could curb COVID-19 and help avert future pandemics

Spikimm and Institut Pasteur Announce That SPKM001, A Next-generation, Highly Potent Anti-SARS-CoV-2 Human Monoclonal Antibody, Effectively Neutralizes the Delta and Delta Plus Variants

Creation of the startup SPIKIMM to develop monoclonal antibodies as an innovative treatment for Covid-19

Events

SpikImm to participate to 44th JP Morgan Annual Healthcare Conference will take place on January 12-15, 2026 in San Francisco, California. James Phillips, will participate in the conference. One-to-one meetings may be arranged by contacting jim.phillips@spikimm.com